Eikon Therapeutics (EIKN) vs Rezolute (RZLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rezolute is the larger company by market cap ($453.1 million vs $411.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EIKN | RZLT |
|---|---|---|
| Share price | $7.59 | $4.69 |
| Market cap | $411.11M | $453.14M |
| 1-day change | +1.20% | +0.97% |
| YTD return | — | +96.61% |
| 1-year return | — | -46.79% |
| 5-year return | — | -30.23% |
| EPS (TTM) | $-8.51 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.40 | $11.46 |
| 52-week low | $7.02 | $1.07 |
| Distance from 52-week high | -56.38% | -59.11% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +224.11% | +109.18% |
| Average volume | 497.76K | 1.50M |
| Shares outstanding | 54.17M | 96.72M |
| Employees | 384 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Eikon Therapeutics
EIKN stock →Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 384 employees
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
EIKN vs RZLT FAQ
Which is bigger, Eikon Therapeutics or Rezolute?
Rezolute (RZLT) is larger, with a market capitalization of $453.14M compared with $411.11M for Eikon Therapeutics (EIKN).
Are Eikon Therapeutics and Rezolute in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Eikon Therapeutics and Biotechnology: Pharmaceutical Preparations for Rezolute.